相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
Bruce A. C. Cree et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Predictively consistent prior effective sample sizes
Beat Neuenschwander et al.
BIOMETRICS (2020)
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
Petra Hundehege et al.
NEURAL REGENERATION RESEARCH (2019)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Johannes Lorscheider et al.
NEUROLOGY (2017)
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
Giancarlo Comi et al.
DRUGS (2017)
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Antonietta Gentile et al.
JOURNAL OF NEUROINFLAMMATION (2016)
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
Catherine O'Sullivan et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
Afsaneh Shirani et al.
NEUROTHERAPEUTICS (2016)
Relapses and disability accumulation in progressive multiple sclerosis
M. Mateo Paz Soldan et al.
NEUROLOGY (2015)
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Antonio Scalfari et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Lysophospholipids and their receptors in the central nervous system
Ji Woong Choi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Fingolimod modulates microglial activation to augment markers of remyelination
Samuel J. Jackson et al.
JOURNAL OF NEUROINFLAMMATION (2011)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Natural history of secondary-progressive multiple sclerosis
Helen Tremlett et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Natural history of multiple sclerosis: a unifying concept
C Confavreux et al.
BRAIN (2006)
Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival
C Jaillard et al.
JOURNAL OF NEUROSCIENCE (2005)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
分享论文
